secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2024-07-09T23:59:59+00:00
Accession:  0001437749-24-022403
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar enrolls first patient in Phase 1 trial of MNPR-101-Zr radiopharmaceutical
--------------------------------------------------------------------------------

- First-in-human Phase 1 dosimetry and imaging trial of MNPR-101-Zr, a uPAR-targeting radiopharmaceutical.
- Up to 12 patients with advanced cancers will be enrolled in the study.
- Trial led by Professor Rodney Hicks at the Melbourne Theranostic Innovation Centre.
- First human study of a radiolabeled monoclonal antibody targeting uPAR.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924022403/0001437749-24-022403-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924022403/mnpr20240708_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-022403

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer